ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1656069
This article is part of the Research TopicAutoimmune Diseases: from molecular mechanisms to therapy developmentView all 24 articles
DNase I alleviates renal inflammatory injury in MRL/lpr mice by inhibiting NETs formation
Provisionally accepted- 1The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
- 2Inner Mongolia Medical University, Hohhot, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE) and represents a frequent and potentially life-threatening clinical condition. The pathogenesis of LN involves multiple immune cell types. Notably, neutrophil extracellular traps (NETs) formation has been closely associated with renal inflammatory injury. However, the underlying pathophysiological mechanisms remain incompletely understood. Methods: We administered DNase I to MRL/lpr mice, monitored signs and renal pathology, quantified gene expression levels, and conducted flow cytometry and RNA-seq analysis. The expression levels of NETs molecular markers and key genes involved in relevant molecular pathways were assessed in both an in vitro cell model treated with PMA and DNase I, as well as in peripheral blood neutrophils from SLE patients, followed by correlation analysis. Results: Following DNase I treatment, the lupus-related manifestations, renal pathology, and renal function were significantly improved in the LN mouse model. The expression levels of MPO and CitH3 were reduced, and the expression of inflammatory damage molecules, including IL-1β, TNF-α, and Kim1, was down-regulated. RNA-seq analysis revealed that the neutrophil and T cell activation and chemotaxis pathways were suppressed, and the infiltration of cytotoxic immune cells in the kidneys was decreased in the DNase I-treated group compared to MRL/lpr mice. In an in vitro model of PMA-induced neutrophil activation, the addition of DNase I inhibited the expression of MPO and CitH3 and down-regulated the expression of inflammatory signaling molecules (TLR4, MYD88, and HMGB1), chemotactic molecule CCL2, and the key molecule of NETs formation, PADI4. Furthermore, the critical molecules PADI4, HMGB1, TLR4, and MYD88 were significantly This is a provisional file, not the final typeset article upregulated in peripheral blood neutrophils from LN patients, and their expression levels in the kidneys of MRL/lpr mice increased in a time-dependent manner. Conclusions: DNase I alleviates renal inflammatory injury by inhibiting the NETs/TLR4/MYD88 cell signaling axis, reducing the formation of NETs and the infiltration of immune inflammatory cells such as T cells and macrophages. These findings may provide a novel clinical prevention and treatment strategy for LN.
Keywords: DNase I, NETs, renal inflammatory injury, MRL/lpr, Lupus Nephritis
Received: 29 Jun 2025; Accepted: 09 Oct 2025.
Copyright: © 2025 Zhang, Xie, Da, Li and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongbin Li, lhbwb73@126.com
Yong Jin, 20212308@immu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.